Marie-Eve Boulay
Overview
Explore the profile of Marie-Eve Boulay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cote A, Beaule R, Boulay M, Guertin J, Boulet L, Godbout K, et al.
J Allergy Clin Immunol Pract
. 2025 Jan;
PMID: 39864739
Background: Because the number of monoclonal antibodies available for severe asthma is growing, specialists currently choose without clear guidelines. Despite increasing knowledge on treatment response to these monoclonal antibodies, making...
2.
Klein M, Plante S, Boulay M, Boulet L, Chakir J
Front Allergy
. 2023 Dec;
4:1296601.
PMID: 38106504
Background: Regulatory T cells (Tregs) contribute to the maintenance of immunological tolerance. There is evidence of impaired function of these cells in people with asthma and allergy. In this study,...
3.
Shin S, Whitmore G, Boulet L, Boulay M, Cote A, Bergeron C, et al.
BMC Pulm Med
. 2023 Dec;
23(1):496.
PMID: 38071285
Background: Some patients with asthma demonstrate normal spirometry and remain undiagnosed without further testing. Objective: To determine clinical predictors of asthma in symptomatic adults with normal spirometry, and to generate...
4.
Laroche J, Pelletier G, Boulay M, Cote A, Godbout K
Int J Chron Obstruct Pulmon Dis
. 2023 May;
18:755-763.
PMID: 37180748
Introduction: Monoclonal antibodies targeting interleukin 5 (IL5) or its receptor (IL5R) are frequently used in severe asthma, in which they reduce exacerbations rate and oral corticosteroids (OCS) exposure. Anti-IL5/IL5Rs have...
5.
Boulet L, Boulay M, Cote A, FitzGerald J, Bergeron C, Lemiere C, et al.
Eur Respir J
. 2022 Nov;
61(3).
PMID: 36396140
Background: Subjects without a previous history of asthma, presenting with unexplained respiratory symptoms and normal spirometry, may exhibit airway hyperresponsiveness (AHR) in association with underlying eosinophilic (type 2 (T2)) inflammation,...
6.
Birs I, Boulay M, Bertrand M, Cote A, Boulet L
Clin Exp Allergy
. 2022 Nov;
53(1):52-64.
PMID: 36317421
Background: Chronic rhinosinusitis with nasal polyposis (CRSwNP) affects a significant number of asthmatic patients and is notably associated with a more difficult-to-control asthma and marked inflammation. We need more studies...
7.
Henry C, Boucher M, Boulay M, Cote A, Boulet L, Bosse Y
Respirology
. 2022 Oct;
28(3):226-235.
PMID: 36210352
Background And Objective: The effect of serial incremental concentrations of methacholine is only slightly cumulative when assessed by spirometry. This limited cumulative effect may be attributed to the bronchodilator effect...
8.
Pelletier G, Godbout K, Boulay M, Boulet L, Morissette M, Cote A
J Asthma Allergy
. 2022 May;
15:691-701.
PMID: 35615256
Purpose: Monoclonal antibodies targeting interleukin-5 (IL5) and its receptor (IL5R), used for severe asthma treatment, reduce eosinophils to almost complete depletion. Fractional exhaled nitric oxide (FeNO), a surrogate marker of...
9.
Cote M, Boulay M, Plante S, Cote A, Chakir J, Boulet L
Allergy Asthma Clin Immunol
. 2022 Mar;
18(1):24.
PMID: 35296352
Background: Allergic rhinitis is a risk factor for asthma development. In asthma, fibroblast progenitors, fibrocytes, are increased in the blood and bronchial mucosa following allergen exposure. These cells may play...
10.
Xu I, Boulay M, Bertrand M, Cote A, Boulet L
Clin Exp Allergy
. 2021 May;
52(1):205-208.
PMID: 34053138
No abstract available.